Hjem › Inflammatorisk tarmsygdom › Missouri
Inflammatorisk tarmsygdom kliniske forsøg i Missouri
7 studier for Inflammatorisk tarmsygdom søger deltagere på steder i Missouri.
Byer i Missouri
Officiel studietekst (engelsk)
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
- Site US-006, St Louis
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 29. sep. 2026 · NCT07845487Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- University Health Truman Medical Center, Kansas City
- og 6 flere
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT03816345Study of DISC-0974-201 in Participants With IBD and Anemia
- KAD Clinical Research, St Louis
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT07368972A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- SSM Health DePaul Hospital- St. Louis, Bridgeton
RekruttererFase 2
Alder 18 til 85 · Alle køn · Opdateret 22. sep. 2026 · NCT06226883A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Washington University School of Medicine, St Louis
RekruttererFase 3
Alder 2 til 19 · Alle køn · Opdateret 22. sep. 2026 · NCT04844606BOOM-IBD2 Pivotal Clinical Trial
- Gateway GI Research (Objective Health), St Louis
Rekrutterer
Alder 18 til 85 · Alle køn · Opdateret 6. aug. 2026 · NCT06571669A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Bridgeton
- Mirador Therapeutics Selected Site, Kansas City
- Mirador Therapeutics Selected Site, Liberty
RekruttererFase 2
Alder 18 til 80 · Alle køn · Opdateret 12. mar. 2026 · NCT07113522Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.